LONDON (ShareCast) - (ShareCast News) - Venn Life sciences said it has had a strong first half, with revenues up 170% on the previous year.
In a very brief trading update, the company, which provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, reported revenue in excess of €4m, up from €1.5 in the same period last year.

Venn said it has experienced continued growth throughout 2015, driven by contract wins amounting to over €9m in the period to 30 June 2015.

Chief executive officer Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally.

"Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth."

Venn is due to release its interim results for the six months ended 30 June, on 22 September.

At 1140 BST, Venn shares were up 4.8% at 20.95p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE